Ago-allosteric modulator of human GLP-2R

The first-in-class, ATP-competitive inhibitor of MAPKAPK5

Novel inhibitor of glutaminase 1 (GLS1) with high binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM), exhibiting a similar in vivo antitumor activity as CB839

Novel potent glucose transporter type 4 (GLUT4) translocation activator, showing a significant blood glucose lowering effect in the severe diabetic mice model

Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4)

Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4)

Glucose transporter inhibitor linker for insulin conjugate

Novel glucose transporter (GLUT) inhibitor, exhibited high antitumor potency through the suppression of glucose uptake (IC 50 : 2.5 μM), while not cytotoxic to prostate and mammary epithelial cells

Metabolite of soy isoflavones, promoting the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover

Novel GM3 derivative, showing excellent migration and invasion inhibitory effects in cells and marked antitumor activity in C57BL/6 mice, involving focal adhesion and ECM-receptor interaction signaling pathways

Selective modulator of gamma-aminobutyric acid(A) receptors

Novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity

Negative control for GMB-805

Novel Tubulin Polymerization Inhibitor

Novel GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of The N-methyl-d-aspartate receptor (NMDAR)

Novel potent and selective RORc inverse agonist

Novel Met inhibitor

Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM)

Novel NMDAR PAM with both an improved pharmacokinetic profile and increased selectivity against AMPARs

Novel inhibitor of nicotinamide phosphoribosyl transferase (NAMPT)

Negative control for GNE-2256

Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM)